Novel AI tools to accelerate cancer research IBM Research Blog

Cancer is the second leading cause of death worldwide[i], with an estimated 18.1 million new cases and 9.6 million deaths attributed to it in 2018[ii]. The search for more effective anti-cancer drugs is a global effort involving academia and industry. In our Computational Systems Biology group at the IBM Research lab in Zurich, we are building machine learning approaches that can potentially help to accelerate our understanding of the leading drivers and molecular mechanisms of these complex diseases, as well as the differences in tumor composition occurring across various cancer types. Our goal is to deepen our understanding of cancer to equip industries and academia with the knowledge that could potentially one day help fuel new treatments and therapies. At the 18th European Conference on Computational Biology (ECCB) and the 27th Conference on Intelligent Systems for Molecular Biology (ISMB) to be held from July 21 -25 in Basel, Switzerland, IBM will present significant, novel research that led to the implementation of three machine learning solutions aimed at accelerating and guiding cancer research.